PTC Therapeutics Target of Unusually High Options Trading (PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT) was the target of some unusual options trading activity on Wednesday. Stock traders bought 3,043 put options on the stock. This is an increase of 2,154% compared to the average volume of 135 put options.

In other news, CEO Stuart Walter Peltz sold 2,230 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $18.03, for a total transaction of $40,206.90. Following the sale, the chief executive officer now directly owns 26,646 shares of the company’s stock, valued at $480,427.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,719 shares of company stock worth $48,848 over the last three months. 8.10% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in PTCT. Macquarie Group Ltd. bought a new position in shares of PTC Therapeutics during the third quarter worth $102,000. Public Employees Retirement System of Ohio bought a new position in shares of PTC Therapeutics during the second quarter worth $142,000. Quantbot Technologies LP bought a new position in shares of PTC Therapeutics during the third quarter worth $150,000. Prudential Financial Inc. bought a new position in shares of PTC Therapeutics during the second quarter worth $201,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of PTC Therapeutics during the third quarter worth $229,000. 86.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on PTCT shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of PTC Therapeutics in a research note on Tuesday, September 26th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of PTC Therapeutics in a research note on Tuesday, September 26th. Citigroup reaffirmed a “buy” rating and issued a $28.00 price objective on shares of PTC Therapeutics in a research note on Wednesday, September 27th. Barclays reduced their price objective on shares of PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, September 29th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating on shares of PTC Therapeutics in a research note on Friday, September 29th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $19.14.

PTC Therapeutics (PTCT) opened at $23.29 on Friday. PTC Therapeutics has a 52 week low of $8.12 and a 52 week high of $23.71. The stock has a market cap of $966.29, a P/E ratio of -8.06 and a beta of 1.23. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98.

TRADEMARK VIOLATION NOTICE: “PTC Therapeutics Target of Unusually High Options Trading (PTCT)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/13/ptc-therapeutics-target-of-unusually-high-options-trading-ptct.html.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit